Achillion Pharmaceuticals Inc., of New Haven, Conn., said presentations at the Asian Pacific Association for the Study of the Liver in Brisbane, Australia, included updated phase II results evaluating a 150-mg loading dose following by 50 mg once daily of ACH-3102, a second-generation NS5A inhibitor, in combination with either once-daily 200 mg or 400 mg of sovaprevir and twice-daily ribavirin in hepatitis C virus (HCV) patients.